Sachi Bio
Sachi Bio is a preclinical-stage biotech developing the Nanoligomer™ platform, a programmable brain-penetrant RNA therapeutic engine targeting neuroinflammation in ALS, Alzheimer's, multiple sclerosis, and related diseases, funded primarily by NASA and DoD grants.
- Company typePrivate
- Founded2019
- HeadquartersLouisville, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Sachi Bio does
Sachi Bio is a preclinical-stage biotechnology company founded in 2019 and headquartered in Erie, Colorado, that develops RNA-based therapeutics for neurodegenerative diseases, cancer, and aging-related disorders. The company's core technology is the Nanoligomer™ platform, a programmable RNA therapeutic discovery engine that enables rapid design, synthesis, validation, and production of targeted therapies capable of crossing the blood-brain barrier via oral, intranasal, injectable, or intravenous routes. The platform supports both gain-of-function (transcriptional activation) and loss-of-function (repression) gene regulation, with claimed high specificity (low nanomolar KD of approximately 3.4 nM), multiplexing across targets such as NF-κB and NLRP3, and a design-to-testing timeline measured in days. Lead candidate NI112 targets chronic neuroinflammation for ALS, Alzheimer's disease, and multiple sclerosis; the pipeline also includes NI111 (MS and inflammatory conditions), NI113 (IL-6 targeting, tested on the ISS), and CK1 (oral microbiome-targeting cocktail for inflammatory bowel disease).
Sachi Bio currently generates no commercial product revenue and is funded entirely through non-dilutive government grants and contracts, primarily from NASA (SBIR Phase I, II, IIE/III, InSPA Phase 1 and 2, and I-Corps) and the U.S. Department of Defense (CDMRP Therapeutic Development Award, 2025). The company has also secured the National Academy of Medicine's Healthy Longevity Global Challenge Award (2023) and features collaborations with Colorado State University, the University of Colorado Anschutz, and ALS United Rocky Mountain. Its go-to-market motion is sales-led through enterprise/government channels rather than traditional pharma commercialization, with the long-term revenue model expected to derive from licensing the Nanoligomer platform and advancing candidates through FDA IND-enabling studies toward clinical development and eventual commercialization. The founding team is led by co-founders Anushree Chatterjee (CEO; transitioned full-time from CU Boulder in 2024) and Prashant Nagpal (CTO/COO), supported by 20+ granted patents and 75+ peer-reviewed publications backing the technology.
Sachi Bio firmographics
Firmographics- Name
- Sachi Bio
- Legal name
- Sachi Bio
- Website
- https://sachibio.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Sachi Bio is a preclinical-stage biotech developing the Nanoligomer™ platform, a programmable brain-penetrant RNA therapeutic engine targeting neuroinflammation in ALS, Alzheimer's, multiple sclerosis, and related diseases, funded primarily by NASA and DoD grants.
- Ownership category
- akta.pro rank
Sachi Bio industry classification
Industry- Product category
- RNA Therapeutics & Biotechnology
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)
- akta.pro secondary industries
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)
Keywords
Where Sachi Bio is headquartered
LocationHeadquarters
- HQ city
- Louisville
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Sachi Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Revenue model
- Therapeutic Development and Licensing: As a preclinical-stage biotechnology company, Sachi Bio currently operates through grant funding and government contracts. Revenue will be generated through licensing its proprietary Nanoligomer™ platform technology and advancing lead therapeutic candidates (NI112, NI111, NI113) through clinical development toward FDA approval and commercialization. The company is working toward IND submission for NI112 targeting ALS, with parallel development for Alzheimer's disease, Multiple Sclerosis, and other neurodegenerative conditions.
- Government Contracts and Grants: Current revenue is derived from government funding including NASA SBIR Phase I, II, IIE, III contracts, NASA InSPA Phase 1 and Phase 2 contracts, and U.S. Department of Defense Therapeutic Development Award. These contracts support R&D activities and platform development.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
Sachi Bio product offering
Product offeringCore offering
Sachi Bio develops the Nanoligomer™ Platform, a programmable RNA therapeutic discovery engine that creates brain-penetrant, targeted therapies for neurodegenerative diseases, cancer, and age-related disorders. The company is advancing lead candidate NI112 toward FDA IND-enabling studies for ALS treatment, with additional candidates targeting Alzheimer's, Multiple Sclerosis, and inflammatory bowel diseases. Revenue is currently generated through government grants and contracts (NASA SBIR, DoD) with future revenue planned through platform licensing and therapeutic commercialization.
Product overview
Sachi Bio is a biotechnology company pioneering RNA-based therapeutics for neurodegenerative diseases, cancer, and aging-related disorders. The company's core offering is the Nanoligomer™ Platform — a programmable RNA therapeutic discovery engine that enables rapid design, synthesis, validation, and production of targeted brain-penetrant therapies. The platform supports both gain-of-function (transcriptional activation) and loss-of-function (repression) gene regulation. The lead therapeutic candidate is NI112, a brain-penetrant RNA therapeutic targeting NF-κB and NLRP3 for neuroinflammation-driven diseases including ALS, Alzheimer's, and multiple sclerosis. Additional candidates include NI111 and NI113 (targeting IL-6) for MS and space-related pathology, and CK1 for gut microbiome targeting in inflammatory bowel disease. The company integrates cutting-edge molecular biology, bioinformatics, and space-based research (ISS organoid studies) to advance its pipeline toward clinical studies.
Differentiator
Problem solved
Functional benefit
Products and services
- Nanoligomer™ Platform Sachi Bio's proprietary programmable RNA therapeutic discovery engine designed to tackle devastating conditions from ALS and Alzheimer's to cancer and aging. The platform enables rapid design, synthesis, validation, and production of targeted therapies with brain-penetrant delivery, high specificity (low nanomolar KD), and multiplexed target identification. Supports both gain-of-function and loss-of-function gene regulation.
- NI112 Lead brain-penetrant RNA therapeutic candidate targeting NF-κB and NLRP3 to combat chronic neuroinflammation, a key driver of ALS, Alzheimer's disease, multiple sclerosis, and protein misfolding disorders. Demonstrated excellent safety-toxicity, brain delivery, and biodistribution profile in IND-enabling studies published in ACS Pharmacology and Translational Science. Being advanced toward FDA IND-enabling studies.
- NI111 Nanoligomer therapeutic candidate targeting NF-κB, TNFR1, and IL-6 for treatment of multiple sclerosis and other inflammatory conditions. Shown to reduce inflammation in human brain models but less effective than NI112 in EAE mouse model.
- NI113 Nanoligomer therapeutic candidate targeting IL-6, tested alongside NI112 in space-based studies aboard the ISS for treatment of space-induced disease pathology in 3D human brain organoids.
- CK1 Microbiome-targeting therapeutic cocktail developed by screening over 90 genes from 41 gut bacteria, designed to restore balance in the gut microbiome for treatment of inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Oral formulation demonstrated protective effects in colitis mouse models.
Quantifiable outcome
- NI112 treatment reduced brain inflammation and improved cognitive function in aged mice and mice with Alzheimer's-like conditions within 4 weeks
- +6 more outcomes
Companies that use Sachi Bio
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Sachi Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature6 records
Sachi Bio partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- U.S. Department of Defense (ALS Research Program)coreDoD awarded Therapeutic Development Award as part of Congressionally Directed Medical Research Programs (CDMRP) to advance Sachi Bio's lead candidate NI112 toward FDA IND-enabling studies for ALS treatment. Award specifically targets chronic neuroinflammation in ALS patients.
- National Academy of MedicinecoreSachi Bio won the NAM-sponsored Healthy Longevity Global Challenge Award for Healthy Aging, recognizing the company's approach to targeting inflammaging as a central mechanism of age-related diseases including Alzheimer's and cognitive decline.
- NASAcoreNASA awarded Sachi Bio Phase I SBIR grant to develop novel therapeutics for radiation countermeasures for deployment in space travel. Partnership expanded through Phase II (2022), Phase IIE/III (2024), and InSPA Phase 1 and Phase 2 contracts (2024-2025) for neuroprotective countermeasures and space-based drug discovery.
- Colorado State UniversitycoreResearch partnership with CSU faculty member Tom LaRocca's Healthspan Biology Lab and postdoctoral fellow Devin Wahl for preclinical validation of NI112 in Alzheimer's and aging models. CSU researchers independently tested Sachi Bio's Nanoligomer drug cocktail targeting NF-κB and NLRP3.
- University of Colorado AnschutzcoreCollaboration with University of Colorado Anschutz scientists for developing oral Nanoligomer treatments for autoimmune diseases. Research published in ACS Pharmacology & Translational Science demonstrated protective effects in colitis models using both injectable and oral formulations of NI112.
- ALS United Rocky MountainminorCommunity partnership through participation in annual ALS Walk events in Denver, Colorado. Sachi Bio participates alongside patients, families, and advocates to raise awareness and demonstrate commitment to finding treatments for ALS.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Sachi Bio competitors and assessment
Company assessmentEmerging players
- Beam Therapeutics: Clinical-stage base editing company developing precision genetic medicines. Comparable to Sachi Bio as an emerging programmable RNA/gene-modulating platform with CNS ambitions, though using a different editing modality.
Broad incumbents
- Moderna: Large-cap mRNA therapeutics and vaccines company exploring RNA-based approaches beyond COVID-19. Represents a broad incumbent that could expand into neurodegeneration with substantially greater resources than Sachi Bio.
- BioNTech: Major mRNA therapeutics company with growing pipeline in oncology and infectious diseases. Comparable to Sachi Bio as a large RNA therapeutics platform, though primarily focused on mRNA vaccines/cancer immunotherapies rather than CNS.
- Biogen: Major neurology-focused pharmaceutical company with leading ALS (Qalsody) and Alzheimer's (Aduhelm/Leqembi) franchises. Relevant incumbent in Sachi Bio's target indications, representing both partnership potential and competitive threat.
Direct peers
- Denali Therapeutics: Biotech focused on neurodegeneration with proprietary blood-brain barrier delivery technology (ATV platform). Directly comparable to Sachi Bio's emphasis on BBB-penetrant therapeutics for ALS and Alzheimer's.
- ProQR Therapeutics: Clinical-stage RNA editing therapeutics company developing Axiomer RNA editing platform. Comparable to Sachi Bio as an emerging RNA therapeutics platform with platform-level optionality across multiple genetic diseases.
- Wave Life Sciences: Clinical-stage RNA therapeutics company developing stereopure oligonucleotides for neurological and rare diseases including ALS and Huntington's. Closely comparable to Sachi Bio's preclinical-stage RNA platform approach to CNS disorders.
- Ionis Pharmaceuticals: Established antisense oligonucleotide (ASO) therapeutics company with multiple approved drugs and a deep CNS pipeline (e.g., Spinraza, tofersen for ALS). Directly comparable to Sachi Bio's RNA-based therapeutic modality for neurodegeneration.
- Translate Bio (Sanofi): mRNA therapeutics company acquired by Sanofi for ~$3.2B, focused on infectious diseases and rare diseases with pulmonary delivery. Comparable to Sachi Bio as an RNA therapeutics platform company, though targeting different indications.
- Alnylam Pharmaceuticals: Leading commercial-stage RNA therapeutics company developing siRNA-based drugs. Comparable to Sachi Bio as a direct RNA therapeutics peer, though focused on RNAi/silencing rather than Sachi's gain-of-function Nanoligomer approach and lacking CNS delivery.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Sachi Bio social profiles
Digital presenceSachi Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sachi Bio leadership team
Management profileNumber of profiles
Profiles10 records
Sachi Bio funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sachi Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sachi Bio
What does Sachi Bio do?
Sachi Bio develops the Nanoligomer™ Platform, a programmable RNA therapeutic discovery engine that creates brain-penetrant, targeted therapies for neurodegenerative diseases, cancer, and age-related disorders. The company is advancing lead candidate NI112 toward FDA IND-enabling studies for ALS treatment, with additional candidates targeting Alzheimer's, Multiple Sclerosis, and inflammatory bowel diseases. Revenue is currently generated through government grants and contracts (NASA SBIR, DoD) with future revenue planned through platform licensing and therapeutic commercialization.
Is Sachi Bio a public or private company?
Sachi Bio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Sachi Bio founded?
Sachi Bio was founded in 2019. It employs 1 to 10 people.
Where is Sachi Bio based?
Sachi Bio is headquartered in Louisville, United States, in the North America region.
How does Sachi Bio make money?
Two revenue lines are on record. Therapeutic Development and Licensing is the primary driver. The others are government Contracts and Grants.
Who are Sachi Bio's main competitors?
Beam Therapeutics is listed as an emerging player. Broad incumbents are Moderna, BioNTech and Biogen. Direct peers are Denali Therapeutics, ProQR Therapeutics, Wave Life Sciences, Ionis Pharmaceuticals, Translate Bio (Sanofi) and Alnylam Pharmaceuticals.
Does Sachi Bio have an API?
No public API is recorded for Sachi Bio.
What industry is Sachi Bio in?
Sachi Bio's product category is RNA Therapeutics & Biotechnology. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.